Presenting clinical and laboratory features of 826 Mayo Clinic patients with ET vs PV vs PMF
| Variables . | ET, n = 292 . | PV, n = 267 . | PMF, n = 267 . | P . | ||
|---|---|---|---|---|---|---|
| ET vs PV . | ET vs PMF . | PV vs PMF . | ||||
| Age, median (range), y | 55 (15-91) | 64 (19-95) | 63 (14-87) | <.0001 | <.0001 | .6 |
| Age ≥60 y, n (%) | 123 (42.1) | 157 (58.8) | 163 (61) | <.0001 | <.0001 | .6 |
| Females, n (%) | 173 (59.2) | 137 (51.3) | 102 (38.2) | .06 | <.0001 | .002 |
| Hemoglobin, median (range), g/dL | 13.9 (6.9-17.9) | 18.4 (15.1-24.5) | 10.6 (5.8-16.1) | <.0001 | <.0001 | <.0001 |
| Leukocytes, median (range), ×109/L | 9.6 (2.8-53.4) | 11.8 (3.8-171.6) | 8.6 (0.8-146.6) | <.0001 | .1 | <.0001 |
| Platelets, median (range), ×109/L | 1000 (454-3460) | 467 (37-1720) | 253 (12-2466) | <.0001 | <.0001 | <.0001 |
| Risk stratification,*% | ||||||
| Low | 37 | 25 | 17 | |||
| Intermediate | 40 | 32 | ||||
| Intermediate-1 | 22 | |||||
| Intermediate-2 | 33 | |||||
| High | 23 | 43 | 28 | |||
| Leukocytes, ≥11 × 109/L, % | 33.1 | 56.5 | 36.3 | <.0001 | .4 | <.0001 |
| Platelets, >1000 × 109/L, % | 52.4 | 7.1 | 2.2 | <.0001 | <.0001 | .008 |
| Abnormal karyotype, “N” evaluable = 610, n (%) | 16 (7.7) | 26 (18.3) | 87 (33.4) | .003 | <.0001 | .001 |
| Palpable splenomegaly, % | 23.6 | 37.3 | 72.6 | .0005 | <.0001 | <.0001 |
| Microcirculatory symptoms, “N” evaluable = 510, n (%) | 52 (17.8) | 89 (40.8) | NA | <.0001 | NA | NA |
| Mutational status, n (%) | NA | .02 | NA | |||
| JAK2 | 157 (53.8) | 149 (55.8) | ||||
| CALR | 89 (30.5) | 64 (24) | ||||
| MPL | 8 (2.7) | 21 (7.9) | ||||
| Triple negative | 38 (13) | 33 (12.3) | ||||
| Variables . | ET, n = 292 . | PV, n = 267 . | PMF, n = 267 . | P . | ||
|---|---|---|---|---|---|---|
| ET vs PV . | ET vs PMF . | PV vs PMF . | ||||
| Age, median (range), y | 55 (15-91) | 64 (19-95) | 63 (14-87) | <.0001 | <.0001 | .6 |
| Age ≥60 y, n (%) | 123 (42.1) | 157 (58.8) | 163 (61) | <.0001 | <.0001 | .6 |
| Females, n (%) | 173 (59.2) | 137 (51.3) | 102 (38.2) | .06 | <.0001 | .002 |
| Hemoglobin, median (range), g/dL | 13.9 (6.9-17.9) | 18.4 (15.1-24.5) | 10.6 (5.8-16.1) | <.0001 | <.0001 | <.0001 |
| Leukocytes, median (range), ×109/L | 9.6 (2.8-53.4) | 11.8 (3.8-171.6) | 8.6 (0.8-146.6) | <.0001 | .1 | <.0001 |
| Platelets, median (range), ×109/L | 1000 (454-3460) | 467 (37-1720) | 253 (12-2466) | <.0001 | <.0001 | <.0001 |
| Risk stratification,*% | ||||||
| Low | 37 | 25 | 17 | |||
| Intermediate | 40 | 32 | ||||
| Intermediate-1 | 22 | |||||
| Intermediate-2 | 33 | |||||
| High | 23 | 43 | 28 | |||
| Leukocytes, ≥11 × 109/L, % | 33.1 | 56.5 | 36.3 | <.0001 | .4 | <.0001 |
| Platelets, >1000 × 109/L, % | 52.4 | 7.1 | 2.2 | <.0001 | <.0001 | .008 |
| Abnormal karyotype, “N” evaluable = 610, n (%) | 16 (7.7) | 26 (18.3) | 87 (33.4) | .003 | <.0001 | .001 |
| Palpable splenomegaly, % | 23.6 | 37.3 | 72.6 | .0005 | <.0001 | <.0001 |
| Microcirculatory symptoms, “N” evaluable = 510, n (%) | 52 (17.8) | 89 (40.8) | NA | <.0001 | NA | NA |
| Mutational status, n (%) | NA | .02 | NA | |||
| JAK2 | 157 (53.8) | 149 (55.8) | ||||
| CALR | 89 (30.5) | 64 (24) | ||||
| MPL | 8 (2.7) | 21 (7.9) | ||||
| Triple negative | 38 (13) | 33 (12.3) | ||||
NA, not available.
Risk stratification in PMF was according to the Dynamic International Prognostic Scoring System plus; in ET, according to the International Prognostic Scoring System; and in PV, according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria. References for these prognostic criteria are included in the main text.